Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14562112rdf:typepubmed:Citationlld:pubmed
pubmed-article:14562112lifeskim:mentionsumls-concept:C0008109lld:lifeskim
pubmed-article:14562112lifeskim:mentionsumls-concept:C0242647lld:lifeskim
pubmed-article:14562112lifeskim:mentionsumls-concept:C0019409lld:lifeskim
pubmed-article:14562112lifeskim:mentionsumls-concept:C1519595lld:lifeskim
pubmed-article:14562112lifeskim:mentionsumls-concept:C1707513lld:lifeskim
pubmed-article:14562112pubmed:issue12lld:pubmed
pubmed-article:14562112pubmed:dateCreated2003-12-12lld:pubmed
pubmed-article:14562112pubmed:abstractTextT(11;18)(q21;q21) results in a chimeric transcript between API2 at 11q21 and MALT1 at 18q21 and is a characteristic chromosomal aberration of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). API2-MALT1 chimeric transcripts are present in approximately one-third of all cases of MALT lymphoma. MALT lymphoma is also known to have variations in histological features and tumor cell proportions. Real-time polymerase chain reaction (PCR) was used to examine number of API2-MALT1 copies in clinical samples for further investigation of the pathophysiology of MALT lymphoma. A total of 13 samples of MALT lymphoma contained API2-MALT1 transcripts from 1.7 x 10(-2) to 1.0 copies/beta-actin copy. These findings were compared to the proportions of tumor cells in genomic VDJ PCR products determined by Southern blotting. Tumor cell ratios varied widely among the patients' samples, and no significant correlation was found between transcript copy number and tumor cell ratio. These results suggest that copy numbers of API2-MALT1 do not reflect tumor cell proportions, and that the number of copies of API2-MALT1 in a tumor cell is different for each clinical sample.lld:pubmed
pubmed-article:14562112pubmed:languageenglld:pubmed
pubmed-article:14562112pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14562112pubmed:citationSubsetIMlld:pubmed
pubmed-article:14562112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14562112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14562112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14562112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14562112pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14562112pubmed:statusMEDLINElld:pubmed
pubmed-article:14562112pubmed:monthDeclld:pubmed
pubmed-article:14562112pubmed:issn0887-6924lld:pubmed
pubmed-article:14562112pubmed:authorpubmed-author:HosokawaYYlld:pubmed
pubmed-article:14562112pubmed:authorpubmed-author:NakamuraTTlld:pubmed
pubmed-article:14562112pubmed:authorpubmed-author:SuzukiHHlld:pubmed
pubmed-article:14562112pubmed:authorpubmed-author:ShikuHHlld:pubmed
pubmed-article:14562112pubmed:authorpubmed-author:NakamuraSSlld:pubmed
pubmed-article:14562112pubmed:authorpubmed-author:SuzukiRRlld:pubmed
pubmed-article:14562112pubmed:authorpubmed-author:SetoMMlld:pubmed
pubmed-article:14562112pubmed:authorpubmed-author:KasugaiYYlld:pubmed
pubmed-article:14562112pubmed:authorpubmed-author:Suguro-Kataya...lld:pubmed
pubmed-article:14562112pubmed:issnTypePrintlld:pubmed
pubmed-article:14562112pubmed:volume17lld:pubmed
pubmed-article:14562112pubmed:ownerNLMlld:pubmed
pubmed-article:14562112pubmed:authorsCompleteYlld:pubmed
pubmed-article:14562112pubmed:pagination2508-12lld:pubmed
pubmed-article:14562112pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:14562112pubmed:meshHeadingpubmed-meshheading:14562112...lld:pubmed
pubmed-article:14562112pubmed:meshHeadingpubmed-meshheading:14562112...lld:pubmed
pubmed-article:14562112pubmed:meshHeadingpubmed-meshheading:14562112...lld:pubmed
pubmed-article:14562112pubmed:meshHeadingpubmed-meshheading:14562112...lld:pubmed
pubmed-article:14562112pubmed:meshHeadingpubmed-meshheading:14562112...lld:pubmed
pubmed-article:14562112pubmed:meshHeadingpubmed-meshheading:14562112...lld:pubmed
pubmed-article:14562112pubmed:meshHeadingpubmed-meshheading:14562112...lld:pubmed
pubmed-article:14562112pubmed:meshHeadingpubmed-meshheading:14562112...lld:pubmed
pubmed-article:14562112pubmed:meshHeadingpubmed-meshheading:14562112...lld:pubmed
pubmed-article:14562112pubmed:meshHeadingpubmed-meshheading:14562112...lld:pubmed
pubmed-article:14562112pubmed:meshHeadingpubmed-meshheading:14562112...lld:pubmed
pubmed-article:14562112pubmed:meshHeadingpubmed-meshheading:14562112...lld:pubmed
pubmed-article:14562112pubmed:meshHeadingpubmed-meshheading:14562112...lld:pubmed
pubmed-article:14562112pubmed:meshHeadingpubmed-meshheading:14562112...lld:pubmed
pubmed-article:14562112pubmed:meshHeadingpubmed-meshheading:14562112...lld:pubmed
pubmed-article:14562112pubmed:meshHeadingpubmed-meshheading:14562112...lld:pubmed
pubmed-article:14562112pubmed:meshHeadingpubmed-meshheading:14562112...lld:pubmed
pubmed-article:14562112pubmed:meshHeadingpubmed-meshheading:14562112...lld:pubmed
pubmed-article:14562112pubmed:meshHeadingpubmed-meshheading:14562112...lld:pubmed
pubmed-article:14562112pubmed:meshHeadingpubmed-meshheading:14562112...lld:pubmed
pubmed-article:14562112pubmed:year2003lld:pubmed
pubmed-article:14562112pubmed:articleTitleHeterogeneous copy numbers of API2-MALT1 chimeric transcripts in mucosa-associated lymphoid tissue lymphoma.lld:pubmed
pubmed-article:14562112pubmed:affiliationDivision of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan.lld:pubmed
pubmed-article:14562112pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14562112pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:330entrezgene:pubmedpubmed-article:14562112lld:entrezgene
entrez-gene:10892entrezgene:pubmedpubmed-article:14562112lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:14562112lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:14562112lld:entrezgene